Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low at $61.28

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $61.28 and last traded at $62.69, with a volume of 927039 shares traded. The stock had previously closed at $64.50.

A number of research analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Sarepta Therapeutics from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 2nd. Barclays cut their target price on shares of Sarepta Therapeutics from $125.00 to $104.00 in a research report on Wednesday, March 2nd. The Goldman Sachs Group cut their target price on shares of Sarepta Therapeutics from $181.00 to $155.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $77.00 to $74.00 and set an “equal weight” rating for the company in a research report on Thursday, May 19th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 21st. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $121.08.

The company has a debt-to-equity ratio of 1.28, a current ratio of 5.56 and a quick ratio of 5.13. The company’s 50-day moving average is $72.22 and its 200-day moving average is $77.17.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.15. The firm had revenue of $210.83 million for the quarter, compared to analysts’ expectations of $208.25 million. Sarepta Therapeutics had a negative net margin of 46.56% and a negative return on equity of 52.06%. The company’s quarterly revenue was up 43.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.10) earnings per share. Analysts expect that Sarepta Therapeutics, Inc. will post -4.59 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Whittier Trust Co. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $58,000. UMB Bank N A MO bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $69,000. IndexIQ Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $61,000. KRS Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $96,000. Finally, Laurel Wealth Planning LLC bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $117,000. 81.43% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.